INC Research Leads Conversation on Clinical Innovation at DIA 2013 Annual Meeting
(Thomson Reuters ONE) -
Global CRO Explores Role of Innovation in Clinical Research,
Offers Strategies to Reduce Costs and Development Time
Raleigh, N.C., June 19, 2013 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a Trusted Process(®) for delivering
reliable results, will be showcasing the latest advances in clinical trial
innovation with an extensive presence at the DIA 2013 Annual Meeting from June
23-27 at the Boston Convention and Exhibition Center. In addition to
participating in 10 educational sessions, INC Research executives will be on-
hand at Booth #81 to discuss the Company's efforts to deliver greater efficiency
and predictability in drug development by leveraging leading technology and
processes.
"Biopharmaceutical companies today are looking for increased transparency, trust
and predictability in the conduct of their clinical trials," said INC Research
CEO Jamie Macdonald. "The DIA Annual Meeting provides an opportunity for us to
come together as an industry and discuss how to overcome some of the more
complex challenges in drug development through clinical process innovations. We
look forward to sharing how INC Research is innovating clinical development by
integrating cutting-edge technologies with our long-standing therapeutic and
operational expertise to accelerate safer products to patients."
Join INC at the Innovation Theater
INC Research's participation in this year's educational program includes
"Innovating Clinical Development Through Data-driven Operational Strategy" as
part of DIA's Innovation Theater. This event will take place June 25 from 3:25 -
3:55 p.m. and will explore the direction clinical research is headed and the
role innovation plays in its new course, as well as offer novel ways to refresh
clinical development operational plans using leading technology. Attendees will
take away strategies to optimize trial delivery, while reducing costs and
development time.
Speaking Program
Additionally, the following INC Research thought leaders will continue the
clinical innovation conversation in the indicated speaker sessions:
* Elaine Taylor, Associate Director, Regulatory Strategy, Consulting, and
Submissions -"Successful Drug Development: Best Practices for Clinical Trial
Design, Agency Interactions, and Regulatory Document Writing" (Pre-Show
Tutorial, June 23 from 1:00 - 4:30 p.m.)
* Alistair Macdonald, Chief Operating Officer - "The State of Clinical
Outsourcing: Managing Risk in Outsourced Clinical Trials" (Forum, June 24
from 11:00 a.m. - 12:30 p.m.)
* Jamie Macdonald, Chief Executive Officer - "Making CRO-Sponsor Partnerships
Work: Executive Roundtable" (Forum, June 25 from 8:00 - 9:30 a.m.)
* Keith Dorricott, Senior Director, Quality Operations - "Fed Up with Tracking
Pointless Metrics? Learn How to Select and Use Metrics that Work"
(Presentation) as part of "Taking Measure of Metrics" (Symposium, June 25
from 1:45 - 3:15 p.m.)
* Andy Townshend, Vice President, Alliance Development - "Is This Trial Worth
It? A Panel Discussion for Sites and Project Managers" (Panel, June 25 from
8:00 - 9:30 a.m.) and "Evolving to FSP: Successfully Transforming Existing
Partnerships into FSP Relationships" (Forum, June 26 from 8:00 - 9:30 a.m.)
* Travis Caudill, Director, Feasibility & Site Identification - "Establishing
the Four Pillars of Data-Driven Feasibility: Best Practices and Tools for
Patient Recruitment Planning" (Presentation) as part of "Understanding
Operational Feasibility: A Discussion of Current Methodologies, Primary
Research Limitations and Opportunities" (Symposium, June 26 from 8:00 -
9:30 a.m.)
* Kathy Bohannon, Executive Director, Strategic Alliances - "Best Practices
for Recruitment and Retention of Pediatric Patients for Clinical Trials"
(Presentation) as part of "Overcoming Unique Challenges of Pediatric
Studies" (Symposium, June 26 from 4:00 - 5:30 p.m.)
* Neil Ferguson, Executive Vice President, Business Development - "Strategic
Partnerships: Emerging Models and Their Impact on Drug Development" (Forum,
June 27 from 9:00 - 10:30 a.m.)
INC Research recently released a new white paper entitled, "Clinical Process
Innovations for New Drug Development: Aligning Clinical Trials with Development
Needs," which explores innovative approaches to bringing drugs to market faster
and reducing development costs. To download a copy of the white paper, click
here.
For more information or to schedule a meeting at DIA 2013, visit the INC
Research website or visit our dedicated DIA Clinical Innovation Facebook page.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to us
for a complete range of customized Phase I to IV programs in all therapeutic
areas and patient populations. Our Trusted Process® methodology and therapeutic
foresight lead customers to better-informed product development decisions, while
our solid site relationships are a critical success factor in delivering
clinical trial results on time and on budget. INC was ranked "Top CRO" by sites
worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey.
INC Research is headquartered in Raleigh, NC. For more information, please
visit www.incresearch.com or follow us at (at)inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1710420]
Unternehmensinformation / Kurzprofil:
Datum: 19.06.2013 - 15:45 Uhr
Sprache: Deutsch
News-ID 271323
Anzahl Zeichen: 6773
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 313 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Leads Conversation on Clinical Innovation at DIA 2013 Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
